Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

被引：34

作者：

Kim, Ji Woong ^{[1
]}

Cho, Yea Bin ^{[1
]}

Lee, Sukmook ^{[1
]}

机构：

[1] Kookmin Univ, Sch Appl Chem, Biopharmaceut Chem Major, Seoul 02707, South Korea

来源：

CELLS | 2021年 / 10卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

GRP94; cancer; therapeutic target; therapy; monoclonal antibody; REGULATED PROTEIN 94; TOLL-LIKE RECEPTORS; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; IMPORTANT BIOLOGIC ACTIVITIES; ENDOPLASMIC-RETICULUM HSP90; MOLECULAR CHAPERONE; PHASE-II; HEAT-SHOCK-PROTEIN-90; INHIBITOR; COLORECTAL-CANCER; HER2; DIMERIZATION;

D O I：

10.3390/cells10030670

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeostasis, and modulating immune system function. Recently, several reports have shown the functional role and clinical relevance of GRP94 overexpression in the progression and metastasis of several cancers. Therefore, the current review highlights GRP94's physiological and pathophysiological roles in normal and cancer cells. Additionally, the unmet medical needs of small chemical inhibitors and the current development status of monoclonal antibodies specifically targeting GRP94 will be discussed to emphasize the importance of cell surface GRP94 as an emerging therapeutic target in monoclonal antibody therapy for cancer.

引用

页码：1 / 19

页数：19

共 170 条

[1] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics [J].